More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$181.35B
EPS
2.68
P/E ratio
32.2
Price to sales
3.7
Dividend yield
2.407%
Beta
0.544285
Previous close
$107.45
Today's open
$106.50
Day's range
$104.59 - $108.18
52 week range
$81.97 - $132.03
show more
CEO
Robert B. Ford
Employees
115000
Headquarters
Abbott Park, IL
Exchange
New York Stock Exchange
Shares outstanding
1.73B
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
Here's How Abbott's EP Business Is Shaping Up for the Rest of 2026
ABT's EP business gains momentum as Volt adoption accelerates and new device launches expand its portfolio despite LAA market weakness.
Zacks Investment Research • Nov 16, 2026

The Winners Inside SCHD - November 2026
The SCHD dividend ETF has extended its year-to-date lead over SPY to more than 20%, despite recent market volatility. October was SCHD's best month of 2026, with a nearly 10% gain; 43 holdings have returned more than twice SPY year-to-date. Twelve holdings announced dividend increases averaging 7.21%, alongside one special dividend; several delivered double-digit hikes.
Seeking Alpha • Nov 17, 2026

Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?
ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.
Zacks Investment Research • Nov 13, 2026

Can UltiSynq Lead Boost Abbott's Cardiac Rhythm Management Business?
ABT's UltiSynq lead combines conduction system pacing and defibrillation, with strong clinical trial results supporting its potential to expand the company's cardiac rhythm management portfolio.
Zacks Investment Research • Nov 11, 2026

Is Trending Stock Abbott Laboratories (ABT) a Buy Now?
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Zacks Investment Research • Nov 11, 2026

3 Medical Device Stocks That Keep Raising Dividends. One Just Hit 55 Years
Hospitals reorder syringes, sensors, and implants whether the economy booms or stalls, and three device makers turn that habit into payouts that grow every year.
24/7 Wall Street • Nov 7, 2026

69 Dividend Champions Ranked By Quality Scores (November 2026)
I present 69 Dividend Champions with Dividend Safety scores of 8+ and rank them using my 9F Quality Scores system. Twenty-two featured Dividend Champions are undervalued, while 21 are overvalued. Forty-nine have quality scores ≥ 7.0, indicating high quality. Top candidates by style: BRO and BMI for growth; BRO, BMI, and RGLD (below $262) for total return; CTBI for income; CAT for past performance.
Seeking Alpha • Nov 7, 2026

3 Dividend Kings to Buy in November and Never Sell
AbbVie is an innovative pharmaceutical leader with an excellent long-term outlook. Abbott Laboratories has made business decisions that should help it overcome recent challenges.
The Motley Fool • Nov 5, 2026

These 12 stocks are good bets to beat the 10-year Treasury over the next decade
Investment newsletters' favorite Dividend Aristocrat stocks
Market Watch • Nov 4, 2026

Abbott Touts Favorable Outcomes In Cardiovascular Device Trials
Abbott Laboratories (NYSE:ABT) reported positive clinical trial results for two investigational cardiovascular devices at the Transcatheter Cardiovascular Therapeutics conference in San Diego, demonstrating high procedural success and low complication rates in patients with irregular heart rhythms and severely calcified coronary arteries.
Benzinga • Nov 2, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Abbott Laboratories commission-free¹. Build wealth for the long term using automated trading and transfers.